Zu‐Xi Yu

This study shows that DLL4/NOTCH1 signaling regulates PPARγ/AKT pathways in PAH, with potential therapeutic implications for vascular remodeling.

This study shows that ARH3 deficiency causes cardiac dysfunction and that rucaparib, a PARP inhibitor, improves cardiac contractility and reduces infarct size in ARH3-deficient mice.